Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryosuke Muroyama

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 22, 2011
[New antivirals against hepatitis C virus(protease inhibitors, polymerase inhibitors, and host factor targeting antivirals)]Naoya Kato, Ryosuke Muroyama
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Viral hepatitis]Naoya Kato, Ryosuke Muroyama, Kaku Goto
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 10, 2012
[New antivirals against hepatitis C virus]Naoya Kato, Ryosuke Muroyama, Kaku Goto
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 14, 2015
[Hepatitis C virus induced hepatocellular carcinoma associated genes]Naoya Kato, Ryosuke Muroyama, Kaku Goto
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 6, 2016
[Development status of DAA against hepatitis C]Naoya Kato, Ryo Nakagawa, Kaku Goto, et al.
Cancer Science|February 24, 2010
Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinomaZhongjie Hu, Ryosuke Muroyama, Norie Kowatari, et al.
Plos One|May 6, 2015
The characteristic changes in hepatitis B virus x region for hepatocellular carcinoma: a comprehensive analysis based on global dataWenwen Li, Kaku Goto, Yasuo Matsubara, et al.
Virus Research|April 17, 2022
Fusion HBx from HBV integrant affects hepatocarcinogenesis through deregulation of ER stress responseRyosuke Muroyama, Ryo Nakagawa, Yasuo Matsubara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis CNarayan Dharel, Naoya Kato, Ryosuke Muroyama, et al.
Virology|August 6, 2014
The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levelsChikako Shibata, Motoko Ohno, Motoyuki Otsuka, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 22, 2011
[New antivirals against hepatitis C virus(protease inhibitors, polymerase inhibitors, and host factor targeting antivirals)]Naoya Kato, Ryosuke Muroyama
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 22, 2013
[Viral hepatitis]Naoya Kato, Ryosuke Muroyama, Kaku Goto
Nihon Rinsho. Japanese Journal of Clinical Medicine|May 10, 2012
[New antivirals against hepatitis C virus]Naoya Kato, Ryosuke Muroyama, Kaku Goto
Nihon Rinsho. Japanese Journal of Clinical Medicine|March 14, 2015
[Hepatitis C virus induced hepatocellular carcinoma associated genes]Naoya Kato, Ryosuke Muroyama, Kaku Goto
Nihon Rinsho. Japanese Journal of Clinical Medicine|February 6, 2016
[Development status of DAA against hepatitis C]Naoya Kato, Ryo Nakagawa, Kaku Goto, et al.
Cancer Science|February 24, 2010
Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinomaZhongjie Hu, Ryosuke Muroyama, Norie Kowatari, et al.
Plos One|May 6, 2015
The characteristic changes in hepatitis B virus x region for hepatocellular carcinoma: a comprehensive analysis based on global dataWenwen Li, Kaku Goto, Yasuo Matsubara, et al.
Virus Research|April 17, 2022
Fusion HBx from HBV integrant affects hepatocarcinogenesis through deregulation of ER stress responseRyosuke Muroyama, Ryo Nakagawa, Yasuo Matsubara, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis CNarayan Dharel, Naoya Kato, Ryosuke Muroyama, et al.
Virology|August 6, 2014
The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levelsChikako Shibata, Motoko Ohno, Motoyuki Otsuka, et al.
Pageof 6